LBI-HTA - Publications - Search - Selective internal radiotherapy using yttrium-90 microspheres for primary and secondary liver malignancies. English version

Nachtnebel, A. and Sotti, G. and Vitale, A. and Perrini, MR. (2011): Selective internal radiotherapy using yttrium-90 microspheres for primary and secondary liver malignancies. English version. Decision Support Document 47.

[img]PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
746Kb
Abstract

Selective internal radiotherapy (SIRT) is a treatment option for patients with primary and secondary liver malignancies. This technique involves the injection of radionuclides directly into the liver artery. If yttrium-90 is used, small particles the so called microspheres are used to deliver the radioactive substance. Two yttrium-90 products are commercially available: resin-microspheres (SIR-Spheres®) and glass microspheres (TheraSphere®). Due to differing blood supply of healthy liver tissue and tumour, the microspheres lodge directly in the tumour and can deliver radiation predominantly to the tumour.
In this review, the efficacy and safety of SIRT was assessed for the treatment of hepatocellular carcinoma (HCC) and for liver metastases of colorectal carcinomas (mCRC), the two most common indications.
2 studies, both reporting on TheraSphere®, were included for efficacy of SIRT for the treatment of HCC. The overall quality of evidence was, according to the GRADE approach, ranked as “very low”. For efficacy of SIRT for mCRC, 3 randomized controlled trials, all using SIR-Spheres®, were included but a judgment on efficacy was hampered as results deviated, different comparators were used and additional therapies were allowed.
Data on safety was considered in 8 studies overall. It seems that careful patient selection is crucial for a safe treatment with SIRT. Overall, the safety profile of this intervention is acceptable.
Based on the evidence identified, the inclusion of TheraSphere® for the treatment of HCC in the catalogue of benefits was not currently recommended. The evidence for the treatment of mCRC with SIR-Spheres® indicated that is more efficacious and as safe as other treatment options. An inclusion in the catalogue of benefits was therefore recommended with restrictions.

Item Type:Decision Support Document
Additional Information:This report is the product of collaboration with the Padova University Hospital, Regione del Veneto/ ITALY and AGE.NA.S - Agenzia Nazionale per i Servizi Sanitari Regionali/ ITALY as an offspring of the European network for Health Technology Assessment (EUnetHTA) Project that was supported by a grant from the European Commission. The responsibility lies with the authors solely; the European Commission is not responsible for any use that may be made of the information contained therein.
Keywords:Selective internal radiotherapy, radiation therapy, liver cancer, liver metastases, yttrium-90, microspheres
Subjects:QZ Pathology > QZ 200-380 Neoplasms.Cysts
WN Radiology. Diagnostic imaging
WI Digestive system > WI 700-770 Liver. Billary tract
Language:English
Series Name:Decision Support Document 47
Deposited on:15 Jul 2011 01:07
Last Modified:15 Jul 2011 01:07

Repository Staff Only: item control page